Table 2.
Drug therapy, treatment modification, and blood pressure control among hypertensive patients attending health centers of Addis Ababa, 2015.
| Drugs | Frequency (%) |
|---|---|
| Monotherapy | 485 (78.7) |
| Methyldopa | 128 (20.8) |
| Enalapril | 123 (20.0) |
| Hydrochlorthiazide | 108 (17.5) |
| Nifedepine | 108 (17.5) |
| Amlodipine | 1 (0.2) |
| Atenolol | 13 (2.1) |
| Propranolol | 4 (0.6) |
| Two drugs combinations | 125 (20.3) |
| Hydrochlorthiazide + Enalapril | 45 (7.3) |
| Hydrochlorthiazide + Nifedepine | 42 (6.8) |
| Hydrochlorthiazide + Atenolol | 13 (2.1) |
| Hydrochlorthiazide + Propranolol | 3 (0.5) |
| Hydrochlorthiazide + Methyldopa | 9 (1.5) |
| Enalapril + Nifedepine | 1 (0.2) |
| Enalapril + Atenolol | 1 (0.2) |
| Enalapril + Propranolol | 2 (0.3) |
| Enalapril + Methyldopa | 2 (0.3) |
| Nifedepine + Methyldopa | 3 (0.5) |
| Atenolol + Methyldopa | 1 (0.2) |
| Atenolol + Amlodipine | 3 (0.5) |
| Three drugs combinations | 6 (1.0) |
| Hydrochlorthiazide + Enalapril + Atenolol | 4 (0.6) |
| Enalapril + Nifedepine + Atenolol | 1 (0.2) |
| Hydrochlorthiazide + Enalapril + Methyldopa | 1 (0.2) |
| Treatment modification | |
| No modification | 523 (84.9) |
| Switch to another drug | 62 (10.1) |
| Addition of drug | 19 (3.1) |
| Increase in dose | 3 (0.5) |
| Decrease in dose | 1 (0.2) |
| Deletion of drug | 2 (0.3) |
| Increase in frequency | 1 (0.2) |
| Decrease in frequency | 5 (0.8) |
| Control of BP | |
| Uncontrolled SBP | 359 (58.3) |
| Uncontrolled DBP | 297 (48.2) |
| Uncontrolled BP | 425 (69) |
BP: blood pressure; SBP: systolic blood pressure; DBP: diastolic blood pressure.